Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update
Pharmacologic Agents To Prevent Low Bone Density
Pharmacologic agents investigated in this systematic review include: the bisphosphonates, which include alendronate, risedronate, zoledronic acid, and ibandronate; peptide hormones (teriparatide); estrogen, in the form of menopausal hormone therapy (MHT); selective estrogen receptor modulators (raloxifene); and biologic agents: denosumab.
Not all drugs currently approved by the U.S. Food and Drug Administration (FDA) for treating patients with LBD were required to demonstrate reduction in fracture risk (e.g., the peptide hormone calcitonin). Furthermore, approval of a different dose, frequency, or route of administration does not require demonstration of reduced fracture risk.
Keywords: Bone | low bone density | bone density | osteoporosis | fracture | osteopenia | skeletal | bisphosphonates | alendronate | risedronate | soledronic acid | ibandronate | teriparatide | parathyroid hormone | SERMs | selective estrogen receptor modulator | menopause | hormonal | estrogen | raloxifene | denosumab | calcitonin
- Newberry SJ, Crandall CC, Gellad WG, et al. Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update to the 2007 Report. Comparative Effectiveness Review No. 53 (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 12-EHC023-EF. Available at www.effectivehealthcare.ahrq.gov/reports/lbd.cfm.
Your slide tray is being processed.